NCT01520870View on ClinicalTrials.gov

Safety and Efficacy of PF-299804 (Dacomitinib), a Pan-HER Irreversible Inhibitor, in Patients With Recurrent Glioblastoma With EGFR Amplification or Presence of EGFRvIII Mutation. A Phase II CT.

PHASE2CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

April 30, 2015

Study Completion Date

March 9, 2017

Conditions
GlioblastomaBrain Tumor, Recurrent
Interventions
DRUG

PF-299804 (Dacomitinib)

Dacomitinib will be administered orally at a dose of 45 mg/day, until disease progression, unacceptable adverse side effects or study end.

Trial Locations (12)

15006

Hospital Universitario A Coruña, A Coruña

18004

Complejo Hospitalario Regional Virgen de Las Nieves, Granada

28034

Hospital Ramón Y Cajal, Madrid

28040

Hospital Clínico San Carlos, Madrid

28041

Hospital Universitario 12 de Octubre, Madrid

35016

Complejo Hospitalario Universitario Insular-Materno Infantil, Las Palmas de Gran Canaria

46009

Hospital Universitario Y Politécnico La Fe, Valencia

08916

Hospital Universitari Germans Trias I Pujol de Badalona, Badalona

08908

Institut Català D'Oncologia L'Hospitalet (Ico), L'Hospitalet de Llobregat

08003

Hospital Del Mar, Barcelona

08025

Hospital de La Santa Creu I Sant Pau, Barcelona

Unknown

Hospital Regional Universitario de Malaga, Málaga

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Grupo Español de Investigación en Neurooncología

OTHER

NCT01520870 - Safety and Efficacy of PF-299804 (Dacomitinib), a Pan-HER Irreversible Inhibitor, in Patients With Recurrent Glioblastoma With EGFR Amplification or Presence of EGFRvIII Mutation. A Phase II CT. | Biotech Hunter | Biotech Hunter